{
    "braf": {
      "name": "BRAF",
      "aliases": [
        "B-Raf proto-oncogene",
        "v-Raf murine sarcoma viral oncogene homolog B"
      ],
      "type": "Gene/Protein",
      "description": "BRAF is a gene that encodes a protein called B-Raf, which is involved in sending signals inside cells that direct cell growth. Mutations in this gene can cause cells to grow and divide abnormally, potentially leading to cancer.",
      "clinicalSignificance": [
        "Critical driver mutation in several cancer types",
        "Targetable by BRAF inhibitor drugs like vemurafenib, dabrafenib, and encorafenib",
        "Most common mutation is V600E, representing ~90% of all BRAF mutations"
      ],
      "associatedDiseases": [
        "Melanoma",
        "Colorectal cancer",
        "Thyroid cancer",
        "Hairy cell leukemia",
        "Langerhans cell histiocytosis"
      ],
      "testMethods": [
        "PCR-based methods",
        "Next-generation sequencing (NGS)",
        "Immunohistochemistry for BRAF V600E"
      ],
      "references": [
        "Davies H, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.",
        "Flaherty KT, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809-819."
      ]
    },
    "egfr": {
      "name": "EGFR",
      "aliases": [
        "Epidermal Growth Factor Receptor",
        "HER1",
        "ErbB1"
      ],
      "type": "Gene/Protein",
      "description": "EGFR is a transmembrane receptor that binds to epidermal growth factor, leading to cellular proliferation, differentiation, and survival. Mutations or overexpression can lead to uncontrolled cell division.",
      "clinicalSignificance": [
        "Key driver in non-small cell lung cancer",
        "Targetable by tyrosine kinase inhibitors like erlotinib, gefitinib, and osimertinib",
        "Common mutations include exon 19 deletions and L858R point mutation"
      ],
      "associatedDiseases": [
        "Non-small cell lung cancer",
        "Colorectal cancer",
        "Glioblastoma",
        "Head and neck squamous cell carcinoma"
      ],
      "testMethods": [
        "PCR-based methods",
        "Next-generation sequencing (NGS)",
        "FISH for gene amplification",
        "Immunohistochemistry for protein expression"
      ],
      "references": [
        "Lynch TJ, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139.",
        "Paez JG, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-1500."
      ]
    },
    "psa": {
      "name": "PSA",
      "aliases": [
        "Prostate-Specific Antigen",
        "Kallikrein-3",
        "KLK3"
      ],
      "type": "Protein/Blood Biomarker",
      "description": "PSA is a protein produced by the prostate gland. Blood levels of PSA can be elevated in men with prostate cancer, but also in non-cancerous conditions like prostatitis and benign prostatic hyperplasia.",
      "clinicalSignificance": [
        "Screening tool for prostate cancer",
        "Monitoring treatment response and recurrence",
        "Higher levels correlate with increased risk of prostate cancer"
      ],
      "normalRange": {
        "value": "<4.0",
        "unit": "ng/mL"
      },
      "associatedDiseases": [
        "Prostate cancer",
        "Benign prostatic hyperplasia",
        "Prostatitis"
      ],
      "testMethods": [
        "Blood test (ELISA)",
        "Free PSA test",
        "PSA velocity (rate of change over time)"
      ],
      "references": [
        "Catalona WJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156-1161.",
        "Thompson IM, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med. 2004;350:2239-2246."
      ]
    },
    "tnf-alpha": {
      "name": "TNF-α",
      "aliases": [
        "Tumor Necrosis Factor alpha",
        "TNF",
        "Cachectin"
      ],
      "type": "Cytokine/Protein",
      "description": "TNF-α is a cytokine involved in systemic inflammation and acute phase reaction. It is produced primarily by activated macrophages, although it can be produced by other cell types.",
      "clinicalSignificance": [
        "Key mediator of inflammatory response",
        "Target for biologic therapies in autoimmune diseases",
        "Elevated in various inflammatory conditions"
      ],
      "normalRange": {
        "value": "<8.1",
        "unit": "pg/mL"
      },
      "associatedDiseases": [
        "Rheumatoid arthritis",
        "Inflammatory bowel disease",
        "Psoriasis",
        "Ankylosing spondylitis",
        "Sepsis"
      ],
      "testMethods": [
        "ELISA",
        "Radioimmunoassay",
        "Flow cytometry"
      ],
      "references": [
        "Feldmann M, et al. TNF alpha as a therapeutic target in rheumatoid arthritis. Circ Res. 2002;90:123-132.",
        "Brennan FM, et al. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet. 1989;2:244-247."
      ]
    },
    "hba1c": {
      "name": "HbA1c",
      "aliases": [
        "Glycated hemoglobin",
        "Hemoglobin A1c",
        "A1C"
      ],
      "type": "Blood Biomarker",
      "description": "HbA1c is formed when hemoglobin joins with glucose in the blood, becoming 'glycated'. By measuring HbA1c, clinicians can get an overall picture of average blood sugar levels over a period of weeks/months.",
      "clinicalSignificance": [
        "Diagnosis of diabetes mellitus",
        "Monitoring long-term glycemic control",
        "Predictor of diabetes complications"
      ],
      "normalRange": {
        "value": "4.0-5.7",
        "unit": "%"
      },
      "associatedDiseases": [
        "Diabetes mellitus",
        "Prediabetes",
        "Metabolic syndrome"
      ],
      "testMethods": [
        "High-performance liquid chromatography (HPLC)",
        "Immunoassay",
        "Capillary electrophoresis"
      ],
      "references": [
        "American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33:S62-S69.",
        "Nathan DM, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986."
      ]
    }
  }
  